Schedules of Controlled Substances: Placement of Zopiclone Into Schedule IV, 16935-16937 [05-6703]
Download as PDF
Federal Register / Vol. 70, No. 63 / Monday, April 4, 2005 / Rules and Regulations
Authority: 21 U.S.C. 360b.
§ 558.55
13. Section 522.1696b is amended by
revising paragraph (d)(2)(iii) to read as
follows:
I
§ 522.1696b Penicillin G procaine aqueous
suspension.
*
*
*
*
*
(d) * * *
(2) * * *
(iii) Limitations. Not for use in horses
intended for food. Milk that has been
taken during treatment and for 48 hours
after the last treatment must not be used
for food.
(A) For Nos. 053501 and 061623: Do
not exceed 7 days of treatment in
nonlactating dairy and beef cattle,
sheep, and swine, or 5 days in lactating
cattle. Discontinue treatment for the
following number of days before
slaughter: Nonruminating cattle
(calves)—7; all other cattle—4; sheep—
8; and swine—6.
(B) For Nos. 010515, 055529, and
059130: Treatment should not exceed 4
consecutive days. Discontinue treatment
for the following number of days before
slaughter: Cattle—10; sheep—9; and
swine—7. A withdrawal period has not
been established for this product in
preruminating calves. Do not use in
calves to be processed for veal.
§ 522.2200
[Amended]
14. Section 522.2200 is amended in
paragraph (e)(3) by adding ‘‘A
withdrawal period has not been
established for this product in
preruminating calves. Do not use in
calves to be processed for veal.’’ at the
end of the paragraph.
I
§ 522.2220
[Amended]
15. Section 522.2220 is amended in
paragraph (a)(3)(iii)(c) by adding ‘‘A
withdrawal period has not been
established for this product in
preruminating calves. Do not use in
calves to be processed for veal.’’ at the
end of the paragraph.
I
§ 522.2640a
[Amended]
16. Section 522.2640a is amended in
paragraph (e)(1)(iii) by adding ‘‘A
withdrawal period has not been
established for this product in
preruminating calves. Do not use in
calves to be processed for veal.’’ at the
end of the paragraph.
I
PART 558—NEW ANIMAL DRUGS FOR
USE IN ANIMAL FEEDS
17. The authority citation for 21 CFR
part 558 continues to read as follows:
I
Authority: 21 U.S.C. 360b, 371.
VerDate jul<14>2003
16:10 Apr 01, 2005
Jkt 205001
[Amended]
18. Section 558.55 is amended in
paragraphs (d)(1)(i)(b) and (d)(1)(ii)(b) by
adding ‘‘A withdrawal period has not
been established for this product in
preruminating calves. Do not use in
calves to be processed for veal.’’ at the
end of the paragraph.
I
Dated: March 25, 2005.
Daniel G. McChesney,
Director, Office of Surveillance and
Compliance, Center for Veterinary Medicine.
[FR Doc. 05–6518 Filed 4–1–05; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
21 CFR Part 1308
[Docket No. DEA–262F]
Schedules of Controlled Substances:
Placement of Zopiclone Into Schedule
IV
Drug Enforcement
Administration, Department of Justice.
ACTION: Final rule.
AGENCY:
SUMMARY: With the issuance of this final
rule, the Deputy Administrator of the
Drug Enforcement Administration
(DEA) places the substance, zopiclone,
including its salts, isomers and salts of
isomers into Schedule IV of the
Controlled Substances Act (CSA). As a
result of this rule, the regulatory
controls and criminal sanctions of
Schedule IV will be applicable to the
manufacture, distribution, dispensing,
importation and exportation of
zopiclone and products containing
zopiclone.
DATES:
Effective Date: April 4, 2005.
FOR FURTHER INFORMATION CONTACT:
Christine Sannerud, Ph.D., Chief, Drug
and Chemical Evaluation Section, Drug
Enforcement Administration,
Washington, DC 20537, (202) 307–7183.
SUPPLEMENTARY INFORMATION: Zopiclone
is a central nervous system depressant
drug. On December 15, 2004, the Food
and Drug Administration (FDA)
approved (S)-zopiclone (or eszopiclone),
the active (S) isomer of zopiclone, for
marketing under the trade name Lunesta
TM. Eszopiclone will be marketed as a
prescription drug product for the
treatment of insomnia.
On January 18, 2005, the Acting
Assistant Secretary for Health,
Department of Health and Human
Services (DHHS), sent the Deputy
Administrator of DEA a letter
recommending that zopiclone and its
PO 00000
Frm 00015
Fmt 4700
Sfmt 4700
16935
isomers be placed into Schedule IV of
the CSA (21 U.S.C. 801 et seq.).
Enclosed with the January 18, 2005,
letter was a document prepared by the
FDA entitled, ‘‘Basis for the
Recommendation for Control of
Zopiclone and its Optical Isomers in
Schedule IV of the Controlled
Substances Act (CSA).’’ The document
contained a review of the factors which
the CSA requires the Secretary to
consider (21 U.S.C. 811(b)).
The correspondence from the Acting
Assistant Secretary for Health to DEA
dated January 18, 2005, confirmed that
FDA approved the New Drug
Application (NDA) for eszopiclone and
issued an approval letter to the NDA
sponsor on December 15, 2004. After a
review of the available data, including
the DHHS recommendation, the Deputy
Administrator of the DEA, in a February
14, 2005, Federal Register notice of
proposed rulemaking (70 FR 7449),
proposed placement of zopiclone into
Schedule IV of the CSA. The proposed
rule provided an opportunity for all
interested persons to submit their
comments, objections, or requests for
hearing to be received by the DEA on or
before March 16, 2005.
Comments Received
DEA received one comment in
response to this notice of proposed
rulemaking. The commenter stated that
the current federal regulations
governing the process of drug control
and approval are excessive and are
interfering with the practice of
medicine.
DEA disagrees. The Controlled
Substances Act contains specific
mandates pertaining to the scheduling
of controlled substances. DEA has
followed all of those mandates regarding
the scheduling of zopiclone, including
receiving from the Secretary of DHHS a
scientific and medical evaluation, and
recommendation, regarding control (21
U.S.C. 811(b)); considering the factors
enumerated in 21 U.S.C. 811(c);
determining, based on the above,
appropriate scheduling for zopiclone
(21 U.S.C. 812(b)); and conducting a
formal rulemaking to schedule
zopiclone (21 U.S.C. 811(a)). In no way
does this scheduling action interfere
with the practice of medicine.
Scheduling of Zopiclone
Relying on the scientific and medical
evaluation and the recommendation of
the Acting Assistant Secretary for
Health, received in accordance with
section 201(b) of the Act (21 U.S.C.
811(b)), and the independent review of
the available data by DEA, and after a
review of the comments received in
E:\FR\FM\04APR1.SGM
04APR1
16936
Federal Register / Vol. 70, No. 63 / Monday, April 4, 2005 / Rules and Regulations
response to the Notice of Proposed
Rulemaking, the Deputy Administrator
of DEA, pursuant to sections 201(a) and
201(b) of the Act (21 U.S.C. 811(a) and
811(b)), finds that:
(1) Zopiclone has a low potential for
abuse relative to the drugs or other
substances in Schedule III;
(2) Zopiclone has a currently accepted
medical use in treatment in the United
States; and
(3) Abuse of zopiclone may lead to
limited physical dependence or
psychological dependence relative to
the drugs or other substances in
Schedule III. (21 U.S.C. 812(b)(4)).
Based on these findings, the Deputy
Administrator of DEA concludes that
zopiclone, including its salts, isomers,
and salts of isomers, warrants control in
Schedule IV of the CSA.
In order to make zopiclone
pharmaceutical products available for
medical use as soon as possible, the
Schedule IV controls of zopiclone will
be effective April 4, 2005. In the event
that the regulations impose special
hardships on the registrants, the DEA
will entertain any justified request for
an extension of time to comply with the
Schedule IV regulations regarding
zopiclone. The applicable regulations
are as follows:
Registration. Any person who
manufactures, distributes, dispenses,
imports, exports, engages in research or
conducts instructional activities with
zopiclone, or who desires to
manufacture, distribute, dispense,
import, export, engage in instructional
activities or conduct research with
zopiclone, must be registered to conduct
such activities in accordance with part
1301 of Title 21 of the Code of Federal
Regulations. Any person who is
currently engaged in any of the above
activities and is not registered with DEA
must submit an application for
registration on or before April 4, 2005,
and may continue their activities until
DEA has approved or denied that
application.
Security. Zopiclone is subject to
Schedule III-V security requirements
and must be manufactured, distributed
and stored in accordance with
§§ 1301.71, 1301.72(b), (c), and (d),
1301.73, 1301.74, 1301.75(b) and (c),
1301.76, and 1301.77 of Title 21 of the
Code of Federal Regulations after April
4, 2005.
Labeling and Packaging. All labels
and labeling for commercial containers
of zopiclone shall comply with
requirements of §§ 1302.03–1302.07 of
Title 21 of the Code of Federal
Regulations.
Inventory. Every registrant required to
keep records and who possesses any
VerDate jul<14>2003
16:10 Apr 01, 2005
Jkt 205001
quantity of zopiclone must keep an
inventory of all stocks of zopiclone on
hand pursuant to §§ 1304.03, 1304.04
and 1304.11 of Title 21 of the Code of
Federal Regulations after April 4, 2005.
Every registrant who desires registration
in Schedule IV for zopiclone is required
to conduct an inventory of all stocks of
the substance on hand at the time of
registration.
Records. All registrants must keep
records pursuant to §§ 1304.03, 1304.04,
1304.21, 1304.22, and 1304.23 of Title
21 of the Code of Federal Regulations
after April 4, 2005.
Prescriptions. All prescriptions for
zopiclone or prescriptions for products
containing zopiclone are to be issued
pursuant to 21 CFR 1306.03–1306.06
and 1306.21–1306.27. All prescriptions
for zopiclone or products containing
zopiclone issued after April 4, 2005, if
authorized for refilling, shall, as of that
date, be limited to five refills and shall
not be refilled after October 3, 2005.
Importation and Exportation. All
importation and exportation of
zopiclone must be in compliance with
part 1312 of Title 21 of the Code of
Federal Regulations after April 4, 2005.
Criminal Liability. Any activity with
zopiclone not authorized by, or in
violation of, the Controlled Substances
Act or the Controlled Substances Import
and Export Act shall be unlawful on or
after April 4, 2005.
Regulatory Certifications
Administrative Procedure Act
The Administrative Procedure Act
permits an agency to make a rule
effective upon the date of publication
where the agency finds good cause
exists and publishes its findings with
the rule (5 U.S.C. 553(d)(3)). As noted
previously, on December 15, 2004, the
Food and Drug Administration (FDA)
approved (S)-zopiclone (or eszopiclone),
the active (S) isomer of zopiclone, for
marketing under the trade name
LunestaTM. Further, on January 18,
2005, the Acting Assistant Secretary for
Health, Department of Health and
Human Services, sent the Deputy
Administrator of DEA a letter
recommending that zopiclone and its
isomers be placed into Schedule IV of
the Controlled Substances Act. Since
this is a new drug not previously
available in the United States, in order
to prevent harm to the public health and
safety by delaying the availability of this
new drug, the Drug Enforcement
Administration finds good cause exists
to make this Final Rule effective
immediately upon publication.
PO 00000
Frm 00016
Fmt 4700
Sfmt 4700
Executive Order 12866
In accordance with the provisions of
the CSA (21 U.S.C. 811(a)), this action
is a formal rulemaking ‘‘on the record
after opportunity for a hearing.’’ Such
proceedings are conducted pursuant to
the provisions of 5 U.S.C. 556 and 557
and, as such, are exempt from review by
the Office of Management and Budget
pursuant to Executive Order 12866,
section 3(d)(1).
Regulatory Flexibility Act
The Deputy Administrator, in
accordance with the Regulatory
Flexibility Act (5 U.S.C. 605(b)), has
reviewed this final rule and by
approving it certifies that it will not
have a significant economic impact on
a substantial number of small entities.
Eszopiclone products will be
prescription drugs used for the
treatment of insomnia. Handlers of
eszopiclone also handle other controlled
substances used to treat insomnia which
are already subject to the regulatory
requirements of the CSA.
Eszopiclone is a new drug in the
United States; recent approval of the
product and its labeling by the FDA will
allow it to be marketed once it is placed
into Schedule IV of the CSA. This final
rule will allow these entities to have
access to a new pharmaceutical product.
Executive Order 12988
This regulation meets the applicable
standards set forth in Sections 3(a) and
3(b)(2) of Executive Order 12988 Civil
Justice Reform.
Executive Order 13132
This rulemaking does not preempt or
modify any provision of state law; nor
does it impose enforcement
responsibilities on any state; nor does it
diminish the power of any state to
enforce its own laws. Accordingly, this
rulemaking does not have federalism
implications warranting the application
of Executive Order 13132.
Unfunded Mandates Reform Act of 1995
This rule will not result in the
expenditure by State, local and tribal
governments, in the aggregate, or by the
private sector, of $115,000,000 or more
in any one year, and will not
significantly or uniquely affect small
governments. Therefore, no actions were
deemed necessary under provisions of
the Unfunded Mandates Reform Act of
1995.
Small Business Regulatory Enforcement
Fairness Act of 1996
This rule is not a major rule as
defined by section 804 of the Small
Business Regulatory Enforcement
E:\FR\FM\04APR1.SGM
04APR1
Federal Register / Vol. 70, No. 63 / Monday, April 4, 2005 / Rules and Regulations
Fairness Act of 1996. This rule will not
result in an annual effect on the
economy of $100,000,000 or more; a
major increase in costs or prices: or
significant adverse effects on
competition, employment, investment,
productivity, innovation, or on the
ability of United States-based
companies to compete with foreign
based companies in domestic and
export markets.
SUMMARY: The Department of State and
the United States Agency for
International Development (USAID) are
removing regulations on employee
responsibilities and conduct (22 CFR
part 10). Most of these regulations have
been superseded or otherwise made
unnecessary by Office of Government
Ethics or Office of Personnel
Management regulations of executive
branch-wide applicability. Certain
sections of the regulations are based on
List of Subjects in 21 CFR Part 1308
Foreign Service Act provisions that have
Administrative practice and
been repealed. Some provisions have
procedure, Drug traffic control,
continuing application and are
Narcotics, Prescription drugs.
published, as modified, in the Foreign
Affairs Manual and other provisions
I Under the authority vested in the
Attorney General by section 201(a) of the simply reference other statutory or
CSA (21 U.S.C. 811(a)), and delegated to regulatory provisions. The Department
the Administrator of DEA by Department of State and USAID are using direct
of Justice regulations (28 CFR 0.100), and final rulemaking for this action because
redelegated to the Deputy Administrator it is expected that there will be no
significant adverse comment on the
pursuant to 28 CFR 0.104, the Deputy
rule.
Administrator hereby amends 21 CFR
part 1308 as follows:
DATES: This direct final rule is effective
on June 3, 2005, without further notice,
PART 1308—SCHEDULES OF
unless the Department of State and
CONTROLLED SUBSTANCES
USAID receive adverse comment by
[AMENDED]
May 4, 2005. If adverse comment is
received, then the Department of State
I 1. The authority citation for 21 CFR
and USAID will publish a timely
part 1308 continues to read as follows:
withdrawal of the direct final rule in the
Authority: 21 U.S.C. 811, 812, 871(b)
Federal Register.
unless otherwise noted.
ADDRESSES: You may submit comments,
I 2. Section 1308.14 is amended by
identified by any of the following
adding a new paragraph (c)(51) to read as methods:
follows:
• E-mail: eirinbergjl@state.gov. You
must include the RIN in the subject line
§ 1308.14 Schedule IV.
of your message.
*
*
*
*
*
• Mail (paper, disk, or CD–ROM
(c) * * *
submissions): Julia L. Eirinberg,
(51) Zopiclone—2784
Attorney-Adviser, Department of State,
*
*
*
*
*
Office of the Assistant Legal Adviser for
Employment Law, 2201 C Street NW,
Dated: March 30, 2005.
Suite 5425, Washington, DC 20520.
Michele M. Leonhart,
• Fax: 202–647–6794.
Deputy Administrator.
Persons with access to the internet
[FR Doc. 05–6703 Filed 3–31–05; 12:24 pm]
may also view this notice and provide
BILLING CODE 4410–09–P
comments by going to the
regulations.gov Web site at: https://
www.regulations.gov/index.cfm.
DEPARTMENT OF STATE
FOR FURTHER INFORMATION CONTACT: Julia
L. Eirinberg, Attorney-Adviser,
AGENCY FOR INTERNATIONAL
Department of State, Office of the
DEVELOPMENT
Assistant Legal Adviser for Employment
Law, 2201 C Street NW., Suite 5425,
22 CFR Part 10
Washington DC 20520; e-mail address:
[Public Notice 5036]
eirinbergjl@state.gov.
RIN 1400–AC09
Removal of Regulations on Employee
Responsibilities and Conduct
State Department and United
States Agency for International
Development.
ACTION: Direct final rule.
AGENCY:
VerDate jul<14>2003
16:10 Apr 01, 2005
The
Department of State and USAID are
removing part 10, ‘‘Employee
Responsibilities and Conduct,’’ from 22
CFR as a result of developments in the
executive branch ethics program and in
other areas of law that have occurred
since the promulgation of part 10 on
May 2, 1978. While the regulations in 22
SUPPLEMENTARY INFORMATION:
Jkt 205001
PO 00000
Frm 00017
Fmt 4700
Sfmt 4700
16937
CFR part 10 also applied to the
International Communication Agency
(ICA), that agency no longer exists and
its functions have been assumed by the
Department of State.
Pursuant to the Ethics in Government
Act of 1978 (5 U.S.C. App.), as
amended, the U.S. Office of Government
Ethics (OGE) now provides overall
direction and leadership in relation to
the executive branch ethics program. In
1989, E.O. 12674 (as modified by E.O.
12731) directed OGE to establish ‘‘a
single, comprehensive, and clear set of
executive-branch standards of conduct’’
and ‘‘a system of nonpublic
(confidential) financial disclosure.’’ On
August 7, 1992, OGE published the
Standards of Ethical Conduct for
Employees of the Executive Branch
(Standards), now codified at 5 CFR part
2635. On April 7, 1992, OGE modified
its existing financial disclosure
regulation, at 5 CFR part 2634, to
incorporate a revised system of
confidential financial disclosure
reporting.
Part 10 of 22 CFR was published in
1978 largely on the basis of a model
standards of conduct regulation at old 5
CFR part 735 that had been promulgated
by the Office of Personnel Management
(OPM) pursuant to Executive Order
11222. The new OGE Standards became
effective February 3, 1993. The
Standards superseded individual
executive agency conduct provisions—
like those in 22 CFR part 10—that had
been issued on the basis of the model
OPM regulation, and superseded much
of the model regulation itself. (As
discussed below in relation to section
10.735–205 of part 10, certain agency
conduct provisions were
‘‘grandfathered’’ or preserved for a few
years after the February 3, 1993,
effective date.) Provisions in the OGE
regulation at 5 CFR part 2634
concerning the revised system of
confidential financial disclosure became
effective on October 5, 1992, and
superseded those portions of individual
executive agency regulations pertaining
to confidential reporting that had been
issued on the basis of the model OPM
regulation. Taken together and as
discussed more fully below, 5 CFR part
2635 and 5 CFR part 2634 superseded
subpart C, subpart D, and much of
subparts A and B of part 10. As also
discussed below, the remaining sections
of subparts A and B have been
superseded or supplanted by other OGE
regulations, are obsolete, or are
unnecessary.
In subpart A of part 10, the statement
of purpose in section 10.735–101 has
been superseded by corollary sections in
5 CFR part 2635 and 5 CFR part 2634
E:\FR\FM\04APR1.SGM
04APR1
Agencies
[Federal Register Volume 70, Number 63 (Monday, April 4, 2005)]
[Rules and Regulations]
[Pages 16935-16937]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-6703]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
21 CFR Part 1308
[Docket No. DEA-262F]
Schedules of Controlled Substances: Placement of Zopiclone Into
Schedule IV
AGENCY: Drug Enforcement Administration, Department of Justice.
ACTION: Final rule.
-----------------------------------------------------------------------
SUMMARY: With the issuance of this final rule, the Deputy Administrator
of the Drug Enforcement Administration (DEA) places the substance,
zopiclone, including its salts, isomers and salts of isomers into
Schedule IV of the Controlled Substances Act (CSA). As a result of this
rule, the regulatory controls and criminal sanctions of Schedule IV
will be applicable to the manufacture, distribution, dispensing,
importation and exportation of zopiclone and products containing
zopiclone.
DATES: Effective Date: April 4, 2005.
FOR FURTHER INFORMATION CONTACT: Christine Sannerud, Ph.D., Chief, Drug
and Chemical Evaluation Section, Drug Enforcement Administration,
Washington, DC 20537, (202) 307-7183.
SUPPLEMENTARY INFORMATION: Zopiclone is a central nervous system
depressant drug. On December 15, 2004, the Food and Drug Administration
(FDA) approved (S)-zopiclone (or eszopiclone), the active (S) isomer of
zopiclone, for marketing under the trade name Lunesta TM. Eszopiclone
will be marketed as a prescription drug product for the treatment of
insomnia.
On January 18, 2005, the Acting Assistant Secretary for Health,
Department of Health and Human Services (DHHS), sent the Deputy
Administrator of DEA a letter recommending that zopiclone and its
isomers be placed into Schedule IV of the CSA (21 U.S.C. 801 et seq.).
Enclosed with the January 18, 2005, letter was a document prepared by
the FDA entitled, ``Basis for the Recommendation for Control of
Zopiclone and its Optical Isomers in Schedule IV of the Controlled
Substances Act (CSA).'' The document contained a review of the factors
which the CSA requires the Secretary to consider (21 U.S.C. 811(b)).
The correspondence from the Acting Assistant Secretary for Health
to DEA dated January 18, 2005, confirmed that FDA approved the New Drug
Application (NDA) for eszopiclone and issued an approval letter to the
NDA sponsor on December 15, 2004. After a review of the available data,
including the DHHS recommendation, the Deputy Administrator of the DEA,
in a February 14, 2005, Federal Register notice of proposed rulemaking
(70 FR 7449), proposed placement of zopiclone into Schedule IV of the
CSA. The proposed rule provided an opportunity for all interested
persons to submit their comments, objections, or requests for hearing
to be received by the DEA on or before March 16, 2005.
Comments Received
DEA received one comment in response to this notice of proposed
rulemaking. The commenter stated that the current federal regulations
governing the process of drug control and approval are excessive and
are interfering with the practice of medicine.
DEA disagrees. The Controlled Substances Act contains specific
mandates pertaining to the scheduling of controlled substances. DEA has
followed all of those mandates regarding the scheduling of zopiclone,
including receiving from the Secretary of DHHS a scientific and medical
evaluation, and recommendation, regarding control (21 U.S.C. 811(b));
considering the factors enumerated in 21 U.S.C. 811(c); determining,
based on the above, appropriate scheduling for zopiclone (21 U.S.C.
812(b)); and conducting a formal rulemaking to schedule zopiclone (21
U.S.C. 811(a)). In no way does this scheduling action interfere with
the practice of medicine.
Scheduling of Zopiclone
Relying on the scientific and medical evaluation and the
recommendation of the Acting Assistant Secretary for Health, received
in accordance with section 201(b) of the Act (21 U.S.C. 811(b)), and
the independent review of the available data by DEA, and after a review
of the comments received in
[[Page 16936]]
response to the Notice of Proposed Rulemaking, the Deputy Administrator
of DEA, pursuant to sections 201(a) and 201(b) of the Act (21 U.S.C.
811(a) and 811(b)), finds that:
(1) Zopiclone has a low potential for abuse relative to the drugs
or other substances in Schedule III;
(2) Zopiclone has a currently accepted medical use in treatment in
the United States; and
(3) Abuse of zopiclone may lead to limited physical dependence or
psychological dependence relative to the drugs or other substances in
Schedule III. (21 U.S.C. 812(b)(4)).
Based on these findings, the Deputy Administrator of DEA concludes
that zopiclone, including its salts, isomers, and salts of isomers,
warrants control in Schedule IV of the CSA.
In order to make zopiclone pharmaceutical products available for
medical use as soon as possible, the Schedule IV controls of zopiclone
will be effective April 4, 2005. In the event that the regulations
impose special hardships on the registrants, the DEA will entertain any
justified request for an extension of time to comply with the Schedule
IV regulations regarding zopiclone. The applicable regulations are as
follows:
Registration. Any person who manufactures, distributes, dispenses,
imports, exports, engages in research or conducts instructional
activities with zopiclone, or who desires to manufacture, distribute,
dispense, import, export, engage in instructional activities or conduct
research with zopiclone, must be registered to conduct such activities
in accordance with part 1301 of Title 21 of the Code of Federal
Regulations. Any person who is currently engaged in any of the above
activities and is not registered with DEA must submit an application
for registration on or before April 4, 2005, and may continue their
activities until DEA has approved or denied that application.
Security. Zopiclone is subject to Schedule III-V security
requirements and must be manufactured, distributed and stored in
accordance with Sec. Sec. 1301.71, 1301.72(b), (c), and (d), 1301.73,
1301.74, 1301.75(b) and (c), 1301.76, and 1301.77 of Title 21 of the
Code of Federal Regulations after April 4, 2005.
Labeling and Packaging. All labels and labeling for commercial
containers of zopiclone shall comply with requirements of Sec. Sec.
1302.03-1302.07 of Title 21 of the Code of Federal Regulations.
Inventory. Every registrant required to keep records and who
possesses any quantity of zopiclone must keep an inventory of all
stocks of zopiclone on hand pursuant to Sec. Sec. 1304.03, 1304.04 and
1304.11 of Title 21 of the Code of Federal Regulations after April 4,
2005. Every registrant who desires registration in Schedule IV for
zopiclone is required to conduct an inventory of all stocks of the
substance on hand at the time of registration.
Records. All registrants must keep records pursuant to Sec. Sec.
1304.03, 1304.04, 1304.21, 1304.22, and 1304.23 of Title 21 of the Code
of Federal Regulations after April 4, 2005.
Prescriptions. All prescriptions for zopiclone or prescriptions for
products containing zopiclone are to be issued pursuant to 21 CFR
1306.03-1306.06 and 1306.21-1306.27. All prescriptions for zopiclone or
products containing zopiclone issued after April 4, 2005, if authorized
for refilling, shall, as of that date, be limited to five refills and
shall not be refilled after October 3, 2005.
Importation and Exportation. All importation and exportation of
zopiclone must be in compliance with part 1312 of Title 21 of the Code
of Federal Regulations after April 4, 2005.
Criminal Liability. Any activity with zopiclone not authorized by,
or in violation of, the Controlled Substances Act or the Controlled
Substances Import and Export Act shall be unlawful on or after April 4,
2005.
Regulatory Certifications
Administrative Procedure Act
The Administrative Procedure Act permits an agency to make a rule
effective upon the date of publication where the agency finds good
cause exists and publishes its findings with the rule (5 U.S.C.
553(d)(3)). As noted previously, on December 15, 2004, the Food and
Drug Administration (FDA) approved (S)-zopiclone (or eszopiclone), the
active (S) isomer of zopiclone, for marketing under the trade name
Lunesta\TM\. Further, on January 18, 2005, the Acting Assistant
Secretary for Health, Department of Health and Human Services, sent the
Deputy Administrator of DEA a letter recommending that zopiclone and
its isomers be placed into Schedule IV of the Controlled Substances
Act. Since this is a new drug not previously available in the United
States, in order to prevent harm to the public health and safety by
delaying the availability of this new drug, the Drug Enforcement
Administration finds good cause exists to make this Final Rule
effective immediately upon publication.
Executive Order 12866
In accordance with the provisions of the CSA (21 U.S.C. 811(a)),
this action is a formal rulemaking ``on the record after opportunity
for a hearing.'' Such proceedings are conducted pursuant to the
provisions of 5 U.S.C. 556 and 557 and, as such, are exempt from review
by the Office of Management and Budget pursuant to Executive Order
12866, section 3(d)(1).
Regulatory Flexibility Act
The Deputy Administrator, in accordance with the Regulatory
Flexibility Act (5 U.S.C. 605(b)), has reviewed this final rule and by
approving it certifies that it will not have a significant economic
impact on a substantial number of small entities. Eszopiclone products
will be prescription drugs used for the treatment of insomnia. Handlers
of eszopiclone also handle other controlled substances used to treat
insomnia which are already subject to the regulatory requirements of
the CSA.
Eszopiclone is a new drug in the United States; recent approval of
the product and its labeling by the FDA will allow it to be marketed
once it is placed into Schedule IV of the CSA. This final rule will
allow these entities to have access to a new pharmaceutical product.
Executive Order 12988
This regulation meets the applicable standards set forth in
Sections 3(a) and 3(b)(2) of Executive Order 12988 Civil Justice
Reform.
Executive Order 13132
This rulemaking does not preempt or modify any provision of state
law; nor does it impose enforcement responsibilities on any state; nor
does it diminish the power of any state to enforce its own laws.
Accordingly, this rulemaking does not have federalism implications
warranting the application of Executive Order 13132.
Unfunded Mandates Reform Act of 1995
This rule will not result in the expenditure by State, local and
tribal governments, in the aggregate, or by the private sector, of
$115,000,000 or more in any one year, and will not significantly or
uniquely affect small governments. Therefore, no actions were deemed
necessary under provisions of the Unfunded Mandates Reform Act of 1995.
Small Business Regulatory Enforcement Fairness Act of 1996
This rule is not a major rule as defined by section 804 of the
Small Business Regulatory Enforcement
[[Page 16937]]
Fairness Act of 1996. This rule will not result in an annual effect on
the economy of $100,000,000 or more; a major increase in costs or
prices: or significant adverse effects on competition, employment,
investment, productivity, innovation, or on the ability of United
States-based companies to compete with foreign based companies in
domestic and export markets.
List of Subjects in 21 CFR Part 1308
Administrative practice and procedure, Drug traffic control,
Narcotics, Prescription drugs.
0
Under the authority vested in the Attorney General by section 201(a) of
the CSA (21 U.S.C. 811(a)), and delegated to the Administrator of DEA
by Department of Justice regulations (28 CFR 0.100), and redelegated to
the Deputy Administrator pursuant to 28 CFR 0.104, the Deputy
Administrator hereby amends 21 CFR part 1308 as follows:
PART 1308--SCHEDULES OF CONTROLLED SUBSTANCES [AMENDED]
0
1. The authority citation for 21 CFR part 1308 continues to read as
follows:
Authority: 21 U.S.C. 811, 812, 871(b) unless otherwise noted.
0
2. Section 1308.14 is amended by adding a new paragraph (c)(51) to read
as follows:
Sec. 1308.14 Schedule IV.
* * * * *
(c) * * *
(51) Zopiclone--2784
* * * * *
Dated: March 30, 2005.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. 05-6703 Filed 3-31-05; 12:24 pm]
BILLING CODE 4410-09-P